- Home
- REFI vs TNGX Comparison
REFI vs TNGX Comparison
Compare REFI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- TNGX
- Stock Information
- Founded
- REFI 2021
- TNGX 2014
- Country
- REFI United States
- TNGX United States
- Employees
- REFI N/A
- TNGX N/A
- Industry
- REFI Real Estate Investment Trusts
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- TNGX Health Care
- Exchange
- REFI Nasdaq
- TNGX Nasdaq
- Market Cap
- REFI 314.2M
- TNGX 317.4M
- IPO Year
- REFI 2021
- TNGX N/A
- Fundamental
- Price
- REFI $15.39
- TNGX $1.76
- Analyst Decision
- REFI Strong Buy
- TNGX Strong Buy
- Analyst Count
- REFI 3
- TNGX 7
- Target Price
- REFI $20.00
- TNGX $12.33
- AVG Volume (30 Days)
- REFI 193.1K
- TNGX 801.9K
- Earning Date
- REFI 03-12-2025
- TNGX 05-07-2025
- Dividend Yield
- REFI 13.32%
- TNGX N/A
- EPS Growth
- REFI N/A
- TNGX N/A
- EPS
- REFI 1.88
- TNGX N/A
- Revenue
- REFI $55,534,183.00
- TNGX $42,069,000.00
- Revenue This Year
- REFI N/A
- TNGX N/A
- Revenue Next Year
- REFI N/A
- TNGX N/A
- P/E Ratio
- REFI $8.23
- TNGX N/A
- Revenue Growth
- REFI N/A
- TNGX 15.17
- 52 Week Low
- REFI $14.82
- TNGX $1.71
- 52 Week High
- REFI $16.47
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- REFI 39.44
- TNGX 33.97
- Support Level
- REFI $15.28
- TNGX $1.80
- Resistance Level
- REFI $15.67
- TNGX $2.04
- Average True Range (ATR)
- REFI 0.30
- TNGX 0.18
- MACD
- REFI -0.07
- TNGX 0.01
- Stochastic Oscillator
- REFI 26.05
- TNGX 20.19
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.